arginyl-glycyl-aspartic acid has been researched along with Parkinsonian Disorders in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broom, L; Jenner, P; Rose, S | 1 |
1 other study(ies) available for arginyl-glycyl-aspartic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicity.
Topics: Animals; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Immunohistochemistry; Mesencephalon; Nerve Growth Factors; Neuroglia; Neurons; Neurotoxins; Oligopeptides; Osteopontin; Parkinsonian Disorders; Rats; Rats, Wistar | 2015 |